Cargando…

Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

OBJECTIVE: Second-line treatment of endometrial cancer is an unmet medical need. We conducted a phase I study evaluating lurbinectedin and doxorubicin intravenously every 3 weeks in patients with solid tumors. The aim of this study was to characterise the efficacy and safety of lurbinectedin and dox...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573419/ https://www.ncbi.nlm.nih.gov/pubmed/34610971 http://dx.doi.org/10.1136/ijgc-2021-002881

Ejemplares similares

Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
por: Kristeleit, Rebecca, et al.
Publicado: (2023)

Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
por: Olmedo, María Eugenia, et al.
Publicado: (2021)

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
por: Calvo, E., et al.
Publicado: (2017)

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
por: Calvo, Emiliano, et al.
Publicado: (2022)

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer
por: Awada, A.H., et al.
Publicado: (2022)

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
por: Subbiah, Vivek, et al.
Publicado: (2022)

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
por: Boni, V., et al.
Publicado: (2022)

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study
por: Fudio, Salvador, et al.
Publicado: (2023)

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
por: Fudio, Salvador, et al.
Publicado: (2020)

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
por: Cruz, Cristina, et al.
Publicado: (2018)

Lurbinectedin for small cell lung cancer
Publicado: (2021)

Lurbinectedin in small cell lung cancer
por: Manzo, Anna, et al.
Publicado: (2022)

Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
por: Poveda, Andres, et al.
Publicado: (2022)

Lurbinectedin-induced thrombocytopenia: the role of body surface area
por: Papachristos, Apostolos, et al.
Publicado: (2022)

Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma
por: Anobile, Dario P., et al.
Publicado: (2021)

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma
por: Gadducci, Angiolo, et al.
Publicado: (2022)

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
por: Gros, Louis, et al.
Publicado: (2021)

ATR inhibition augments the efficacy of lurbinectedin in small‐cell lung cancer
por: Schultz, Christopher W, et al.
Publicado: (2023)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

Specific Effects of Trabectedin and Lurbinectedin on Human Macrophage Function and Fate—Novel Insights
por: Povo-Retana, Adrián, et al.
Publicado: (2020)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Lurbinectedin improves macular edema in a case of central retinal vein occlusion()
por: Simona, Filippo, et al.
Publicado: (2022)

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity
por: Povo-Retana, Adrián, et al.
Publicado: (2023)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023)

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
por: Kauffmann-Guerrero, Diego, et al.
Publicado: (2020)

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2015)

Comparison of Doxorubicin Plus Docetaxel Neoadjuvant Chemotherapy with Doxorubicin Plus Vinorelbine in Primary Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells
por: Costanzo, Federico, et al.
Publicado: (2022)

An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer
por: Patel, Shetal, et al.
Publicado: (2021)

Methylsulfonylmethane sensitizes endometrial cancer cells to doxorubicin
por: Kowalska, Karolina, et al.
Publicado: (2020)

Lurbinectedin, a DNA minor groove inhibitor for neuroendocrine neoplasms beyond small cell lung cancer
por: Bhamidipati, Deepak, et al.
Publicado: (2023)

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
por: Hanvesakul, Raj, et al.
Publicado: (2023)

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer
por: Basté Rotllan, Neus
Publicado: (2022)

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors
por: Poveda, Andres, et al.
Publicado: (2021)

Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report
por: Cortesi, Laura, et al.
Publicado: (2022)

Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
por: Fernández-Teruel, Carlos, et al.
Publicado: (2021)

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
por: Lima, Michelle, et al.
Publicado: (2016)

Trabectedin and Lurbinectedin Extend Survival of Mice Bearing C26 Colon Adenocarcinoma, without Affecting Tumor Growth or Cachexia
por: Aquila, Giorgio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pn2r8cog6ds9o2v1fbrlu1j21v